Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxaneยฎ is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-03-15
- Target Recruit Count
- 70
- Registration Number
- NCT00019019
- Locations
- ๐บ๐ธ
NCI - Medical Oncology Clinical Research Unit, Bethesda, Maryland, United States
๐บ๐ธWarren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Combination Chemotherapy in Treating Men With Germ Cell Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-03-06
- Target Recruit Count
- 498
- Registration Number
- NCT00003643
- Locations
- ๐ฉ๐ช
Klinikum der Stadt Mannheim, Mannheim, Germany
๐ง๐ชUniversitair Ziekenhuis Antwerpen, Edegem, Belgium
๐ฉ๐ฐAarhus Universitetshospital - Aarhus Sygehus, Aarhus, Denmark
Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
- Conditions
- Locations
- ๐ง๐ช
U.Z. Gasthuisberg, Leuven, Belgium
๐จ๐ฆCancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada
๐ฎ๐นIstituto Nazionale per lo Studio e la Cura dei Tumori, Milano (Milan), Italy
Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00042835
- Locations
- ๐บ๐ธ
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT00003569
- Locations
- ๐บ๐ธ
University of Chicago Cancer Research Center, Chicago, Illinois, United States
๐บ๐ธSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
๐บ๐ธRoswell Park Cancer Institute, Buffalo, New York, United States
S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 354
- Registration Number
- NCT00004011
- Locations
- ๐บ๐ธ
Abramson Cancer Center at University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
๐บ๐ธMount Diablo Medical Center, Concord, California, United States
๐จ๐ฆDoctor Leon Richard Oncology Centre, Moncton, New Brunswick, Canada
Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00002913
- Locations
- ๐บ๐ธ
Gynecologic Oncology Group of Arizona, Phoenix, Arizona, United States
Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00042809
- Locations
- ๐บ๐ธ
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas, United States
S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 399
- Registration Number
- NCT00016406
- Locations
- ๐บ๐ธ
Lenoir Memorial Cancer Center, Kinston, North Carolina, United States
๐บ๐ธHolland Community Hospital, Holland, Michigan, United States
๐บ๐ธGood Samaritan Cancer Center, Puyallup, Washington, United States
Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 756
- Registration Number
- NCT00005838
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.